Enhancement of Anti-Herpetic Activity of Antisense Phosphorothioate Oligonucleotides 5′ End Modified with Geraniol

References

• Akhtar S., Shoji Y., Juliano R. L. Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides. Gene Regulation: Biology of antisense RNA and DNA, R. P. Erickson, J. G. Izant. Raven Press. Ltd., New York 1992; 133–145
   Google Scholar
• Bennett C. F., Chang M-Yi., Chan H., Shoemaker J. E.E., Mirabelli C. K. Cationic lipid enhance cellular uptake and activity phosphorothioate antisense oligonucleotides. Molecular Pharmacology 1992; 41: 1023–1033
   PubMed Web of Science ®Google Scholar
• Bishop J. S., Guy Caffey J. K., Ojwang J. O., Smith S. R., Hogan M. E., Cossum P. A., Rando R. F., Chaudhary N. Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide. J. Biol Chem. 1996; 271: 5698–5703
   PubMed Web of Science ®Google Scholar
• Buckheit R. W., Robertson J. L., Lackman Smith C., Wyatt J. R., Vickers T. A., Ecker D. J. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum Retroviruses 1994; 10: 1497–1506
   PubMed Web of Science ®Google Scholar
• Burgee T. L., Fisher E. F., Ross S. L., Bready J. V., Quian Y-S., Bayewitch L. A., Cohen A. M., Herrera C. J., Hu S. S-F., Kramer T. B., Lott F. D., Martin F. H., Pierce G. F., Simonet L., Farrell C. L. The anti proliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl. Acad. Sci USA 1995; 92: 4051–4055
   PubMed Web of Science ®Google Scholar
• Crooke S. T. Oligonucleotide therapy. Current Opinion in Biothecnology 1992; 3: 656–661
   PubMed Web of Science ®Google Scholar
• Farrell C. L., Bready J. V., Kaufman S. A., Qian Y. X., Burgess T. L. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antisense Res Dev. 1995; 5: 175–183
   PubMedGoogle Scholar
• Iversen P. L., Zhu S., Meyre A., Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 1992; 2: 211–222
   PubMedGoogle Scholar
• Liang W. W., Shi X., Despande D., Malanga C. J., Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim. Biophys Acta. 1996; 1279: 227–234
   PubMed Web of Science ®Google Scholar
• Loke S. L., Stein C. A., Zhang X. H., Mori K., Nakanishi M., Subasinghe C., Cohen J. S., Neckers L. M. Characterization of oligonucleotide transport into living cells. Proc Natl Acd Sci. 1989; 86: 3474–3478
   PubMed Web of Science ®Google Scholar
• Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. S., Broder S. Phosphorothioate analogues of oligodeoxynucleotides:inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci. USA. 1987; 84: 7706–7710
   PubMed Web of Science ®Google Scholar
• Nagel K. M., Holstand S. G., Isenberg K. E. Oligonucleotides pharmacology: an antigene strategy. Pharmacotherapy 1993; 13: 177–188
   PubMed Web of Science ®Google Scholar
• Saison-Behmoaras T. B., Rey T. I., Chassignol M., Thuoog N. T., Helene C. Short modified antisense oligonucleotides directed against Haras point mutation induce selective cleavage of the mRNA and inhibit T24 cell proliferation. EMBO J. 1991; 10: 1111–1118
   PubMed Web of Science ®Google Scholar
• Shoji Y., Shimada J., Mizushima Y., Iwasawa A., Nakamura Y., Inouye K., Azuma T., Sakurai M., Nishimura T. Cellular uptake and biological effects of antisense oligodeoxy-nucleotide analogs targeted to herpes simplex virus. Antimicrob. Agents Chemother 1996; 40: 1670–1675
   PubMed Web of Science ®Google Scholar
• Shoji Y., Iwatani W., Tamura N., Norimatsu M., Araki N., Hase H., Toriyama S., Wakamatsu Y., Miyanaga Y., Shimada J., Mizushima Y. Study of efficacy of antisense oligonucleotide on rabbit herpes cornea keratitis. Jpn J. Clin. Pharmacol Ther. 1996; 27: 309–310
   Google Scholar
• Stein C. A., Cheng Y-C. Antisense oligonucleotides as therapeutic agents—Is the bullet really magical?. Science 1993; 261: 1004–1012
   PubMed Web of Science ®Google Scholar
• Storey A., Oates D., Banks L., et al. Antisense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papilloma virus type 16. Nucl Acids Res. 1991; 19: 4109–4114
   PubMed Web of Science ®Google Scholar
• Svinarchuk F. P., Konevetz D. A., Pliasunova O. Z., Pokrovsky A. G., Vlassov V. V. Inhibition of HIV proliferation in MT-4 cells by antisense oligonucleotide conjugated to Lipophilic groups. Biochimie. 1993; 75: 49–54
   PubMed Web of Science ®Google Scholar
• Taniura N., Iwatani W., Shoji Y., Norimatsu M., Shimada J., Mizushima Y. Antiviral effects of phosphorothioate oligonucleotides complementary to 3' splice region of herpes simplex virus immediate early pre-mRNA5. Nucleic Acids Symposium Series 1994; 31: 73–74
   Google Scholar
• Taylor M. F., Paulauskis J. D., Weller D. D., Kobzik L. In vitro efficacy of morpholino-mediated antisense oligomers directed against tumor necrosis factor-alphamRNA. J. Biol. Chem. 1996; 271: 17445–17452
   PubMed Web of Science ®Google Scholar
• Wagner R. W. Gene inhibition using antisense oligonucleotides. Nature 1994; 372: 333–335
   PubMed Web of Science ®Google Scholar
• Yakubov L. A., Deeva E. A., Zarytova V. F., Ivanova E. M., Ryte A. S., Yurchenko L. V., Vlassov V. V. Mechanism of oligonucleotide uptake by cells involvement of specific receptors. Proc Natl Acad. Sci USA 1989; 86: 6454–6458
   PubMed Web of Science ®Google Scholar